Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Clinical Breast Cancer

Volumn 17, Issue 1, 2017, Pages 61-69.e3

  Takahashi, Hiroyo ^a   Kagara, Naofumi ^a   Tanei, Tomonori ^a   Naoi, Yasuto ^a   Shimoda, Masafumi ^a   Shimomura, Atsushi ^a   Shimazu, Kenzo ^a   Kim, Seung Jin ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnostic marker; OS MSP; Predictive marker; RASSF1A methylation; Tumor burden

Indexed keywords

ANASTROZOLE; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FLUOROURACIL; GOSERELIN; LETROZOLE; METHYLATED CIRCULATING TUMOR DNA; PACLITAXEL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DNA METHYLATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROMOTER REGION; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; FOLLOW UP; GENETICS; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR EMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

EID: 84979697046     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2016.06.006     Document Type: Article

References (38)

1. 1 Crowley, E., Di Nicolantonio, F., Loupakis, F., et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 (2013), 472–484.
2. 2 van der Vaart, M., Pretorius, P.J., Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137 (2008), 18–26.
3. 3 Diaz, L.A., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
4. 4 Schwarzenbach, H., Pantel, K., Circulating DNA as biomarker in breast cancer. Breast Cancer Res, 17, 2015, 136.
5. 5 Fleischhacker, M., Schmidt, B., Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775 (2007), 181–232.
6. 6 Schwarzenbach, H., Hoon, D.S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11 (2011), 426–437.
7. 7 Lim, S.H., Becker, T.M., Chua, W., et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett 346 (2014), 24–33.
8. 8 Müller, H.M., Widschwendter, A., Fiegl, H., et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63 (2003), 7641–7645.
9. 9 Tan, S.H., Ida, H., Lau, Q.C., et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 18 (2007), 1225–1230.
10. 10 Fackler, M.J., Lopez Bujanda, Z., Umbricht, C., et al. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74 (2014), 2160–2170.
11. 11 Hoque, M.O., Feng, Q., Toure, P., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24 (2006), 4262–4269.
12. 12 Fiegl, H., Millinger, S., Mueller-Holzner, E., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65 (2005), 1141–1145.
13. 13 Sharma, G., Mirza, S., Parshad, R., et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87 (2010), 83–91.
14. 14 Brooks, J.D., Cairns, P., Shore, R.E., et al. DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case–control study. Cancer Epidemiol 34 (2010), 717–723.
15. 15 Matuschek, C., Bölke, E., Lammering, G., et al. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 15 (2010), 277–286.
16. 16 Kloten, V., Becker, B., Winner, K., et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res, 15, 2013, R4.
17. 17 Molina, R., Auge, J.M., Farrus, B., et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 56 (2010), 1148–1157.
18. 18 Yamamoto, N., Nakayama, T., Kajita, M., et al. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 132 (2012), 165–173.
19. 19 Fujita, N., Nakayama, T., Yamamoto, N., et al. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 83 (2012), 273–282.
20. 20 Dawson, S.J., Tsui, D.W., Murtaza, M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368 (2013), 1199–1209.
21. 21 Beckmann, M.W., Blohmer, J.U., Costa, S.D., et al. Zurich consensus: German expert opinion on the St Gallen votes on 15 March 2009 (11th International Conference at St Gallen: Primary Therapy of Early Breast Cancer). Breast Care (Basel) 4 (2009), 109–116.
22. 22 Bottini, A., Berruti, A., Tampellini, M., et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol 18 (1997), 301–310.
23. 23 Wang, Y.J., Huang, X.Y., Mo, M., et al. Serum tumor marker levels might have little significance in evaluating neoadjuvant treatment response in locally advanced breast cancer. Asian Pac J Cancer Prev 16 (2015), 4603–4608.
24. 24 Avraham, A., Uhlmann, R., Shperber, A., et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131 (2012), E1166–E1172.
25. 25 Sharma, G., Mirza, S., Parshad, R., et al. DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol 33 (2012), 1837–1843.
26. 26 Olsson, E., Winter, C., George, A., et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7 (2015), 1034–1047.
27. 27 Garcia-Murillas, I., Schiavon, G., Weigelt, B., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med, 7, 2015, 302ra133.
28. 28 Fujita, N., Kagara, N., Yamamoto, N., et al. Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis. Oncol Lett 8 (2014), 397–403.
29. 29 Elston, C.W., Ellis, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41 (2002), 154–161.
30. 30 Symmans, W.F., Peintinger, F., Hatzis, C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25 (2007), 4414–4422.
31. 31 Salgado, R., Denkert, C., Demaria, S., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26 (2015), 259–271.
32. 32 Lo, Y.M., Zhang, J., Leung, T.N., et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64 (1999), 218–224.
33. 33 Diehl, F., Schmidt, K., Choti, M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14 (2008), 985–990.
34. 34 Yu, S.C., Lee, S.W., Jiang, P., et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem 59 (2013), 1228–1237.
35. 35 Tamkovich, S.N., Cherepanova, A.V., Kolesnikova, E.V., et al. Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci 1075 (2006), 191–196.
36. 36 Tsumita, T., Iwanaga, M., Fate of injected deoxyribonucleic acid in mice. Nature 198 (1963), 1088–1089.
37. 37 Zurita, M., Lara, P.C., del Moral, R., et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer, 10, 2010, 217.
38. 38 Kristiansen, S., Jørgensen, L.M., Hansen, M.H., et al. Concordance of hypermethylated DNA and the tumor markers CA 15-3, CEA, and TPA in serum during monitoring of patients with advanced breast cancer. Biomed Res Int, 2015, 2015, 986024.